Meil on hea meel teada anda, et Asper Biogene on valmis saanud uue farmakogeneetilise testi – Antidepressandid PGx – geenide ja ravimite omavahelise mõju hindamiseks.
Antidepressandid PGx test koosneb hoolega valitud ja rangelt tõenduspõhistest geneetilistest markeritest. Testi tulemused sisaldavad soovitusi selektiivsete serotoniini tagasihaarde inhibiitorite (SSTI) ja tritsükliliste antidepressantide (TTA) dooside optimeerimiseks vastavalt Clinical Pharmacogenetics Implemetation Consortium (CPIC) ravijuhistele. Täpsem info www.asperbio.com/asper-pharmacogenetics/antidepressandid-pgx/
We are pleased to announce that Asper Biogene has launched a new pharmacogenetic test – Antidepressants PGx – for assessing metabolic response to antidepressant medications.
Antidepressants PGx test includes carefully selected and strictly evidence-based genetic markers. The test provides dosing recommendations for selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) based on guidelines published by Clinical Pharmacogenetics Implementation Consortium (CPIC). Read more at www.asperbio.com/asper-pharmacogenetics/antidepressants-pgx/
Microcephaly and hereditary spastic paraplegia panels have been updated with multiple new genes. Learn more at www.asperbio.com/asper-neurogenetics
All NGS panels in our testing menu now include CNV analysis. Panels for frontotemporal dementia, tuberous sclerosis, microcephaly, and hereditary spastic paraplegia cover the analysis of clinically relevant non-coding variants. Learn more at www.asperbio.com/asper-neurogenetics
Asper Biogene is attending the Annual Ataxia Conference, 10-13 March, organised by the National Ataxia Foundation. The conference will be held online and brings together leading ataxia experts. Do not miss the opportunity to get informed about recent research on ataxias and developments in treatment targets and diagnostics.
Take a close look at our virtual booth and learn about Asper Biogene’s genetic testing options for different types of ataxias. Come as you are: Ataxia unmasked!
Download a leaflet of ataxia testing options
Download a table of tested genes and diseases
We have launched an updated Asper Dysmorphology menu. New phenotypically relevant disease-causing genes have been added to many of the panels including brain malformation, microcephaly, skeletal dysplasia, craniosynostosis and several other panels. Visit www.asperbio.com/asper-dysmorphology to see the whole list of tests.
Asper Dermatology panels have been updated with multiple new genes highly relevant for
differential diagnosis. List of the updated panels is available www.asperbio.com/asper-dermatology
We have updated our Cutis Laxa panel. Visit www.asperbio.com/cutis-laxa-ngs-panel/ to see the new version of the test.
Left Ventricular Noncompaction Cardiomyopathy panel covers the analysis of 13 genes. Read more at www.asperbio.com/left-ventricular-noncompaction-cardiomyopathy
We now offer a new test for Congenital Muscular Dystrophy, which covers 29 genes and disease-associated non-coding variants. Cornelia de Lange Syndrome and Limb-Girdle Muscular Dystrophy panels also include the analysis of non-coding variants. In addition, we have added genes to the Limb-Girdle Muscular Dystrophy gene set. Learn more at www.asperbio.com/asper-neurogenetics/
We have expanded our testing options for different types of hereditary ataxia. NGS panel now covers 148 genes and selected non-coding variants associated with spinocerebellar ataxia, episodic ataxia, and cerebellar ataxia. Repeat expansion analysis is available for 14 genes. CNVs are detected based on sequencing data or by Chromosomal Microarray Analysis. Mitochondrial genome sequencing can also be performed to determine the specific genetic cause of hereditary ataxia. Read more at https://www.asperbio.com/asper-neurogenetics/hereditary-ataxia/
Asper Biogene is working on the new project – „Prototype development of pharmacogenetic test“.
1. To develop a prototype of pharmacogenetic test to maximize drug efficacy and reduce adverse drug reactions for most common drugs (at least 30 drugs) listed in the internationally agreed pharmacogenetic clinical practice guidelines.
2. To develop medical informatics tools for the automatic generation and sharing of web-based pharmacogenetic test reports with doctors and patients through Health and Welfare Information Systems Centre (HWISC) database.
Project period: 06.07.2020 – 06.01.2021
Project has been supported by Enterprise Estonia (EAS) from The European Regional Development Fund. Financial support is up to 24 500,00 Euros.
We have updated the cataract panel with 14 new genes. Visit www.asperbio.com/asper-ophthalmics/cataract-ngs-panel/ for more detailed information.
Dystonia, Charcot-Marie-Tooth disease, and spinocerebellar ataxias panels now include the analysis of disease-associated non-coding variants. Visit www.asperbio.com/asper-neurogenetics to learn more.
Female infertility and male factor infertility panels have undergone an extensive upgrade. The panels now consist of 128 and 138 genes respectively. Female infertility panel also contains testing of CGG trinucleotide repeat in the FMR1 gene. Please see www.asperbio.com/asper-reprogenetics/ for more information.
We now offer a new panel for testing congenital fibrosis of extraocular muscles. In addition, we have updated our comprehensive eye diseases panel to include up to 288 genes. Discover more at www.asperbio.com/asper-ophthalmics
We now offer a new test for Mucopolysaccharidosis. Comprehensive panel for lysosomal storage diseases is also available. Discover more at https://www.asperbio.com/asper-metabolic-disorders/
Several NGS panels have been updated, including panels for Brain Malformations, Spinocerebellar Ataxias, and Sensorineural Hearing Loss. Find more about updates at www.asperbio.com/NGS-panels
Congenital Adrenal Hyperplasia testing is now available. The test includes sequencing of the coding region and deletion/duplication analysis of the CYP21A2 gene. Read more at www.asperbio.com/asper-endocrinology/CAH
Male Factor Infertility NGS panel has been updated with the AR gene. Visit www.asperbio.com/asper-reprogenetics/male-factor-infertility/ to see the complete list of genes.
We have launched a new NGS panel for hypomagnesemia. The new panel with CNV analysis is designed to detect 19 genes implicated in hypomagnesemia and related conditions. The list of genes is available www.asperbio.com/asper-nephrology/hypomagnesemia/
We have added Female Infertility NGS panel to our Asper Reprogenetics testing menu. List of genes covered by the panel is available www.asperbio.com/asper-reprogenetics/female-infertility-ngs-panel/
In critical situation, due to COVID-19 faced by many countries we would like to ensure that we continue providing you with genetic testing services. Our key goal is to continuously offer diagnostic solutions that support healthcare professionals with valuable information and thus contribute to improving patient care. We are committed to maintain the highest level of quality standards in all operations.
In our everyday practice, we follow the WHO guidelines and protective measures of national health authorities to establish safety and health of our employees and customers.
Our laboratory team, clinical and scientific teams are operational and available as usual. As well as customer service will continue to offer assistance. If any new information under these changing circumstances become available we will notify you as soon as possible.
Be safe and healthy! If we can be any of assistance, please do not hesitate to contact us.
Familial Hemiplegic Migraine NGS panel is now available. Visit www.asperbio.com/familial-hemiplegic-migraine-ngs-panel/ to learn more!
Multiple new genes have been added to our mitochondrial diseases nuclear gene set. Visit www.asperbio.com/asper-neurogenetics/mitochondrial-diseases/ to see the complete list of genes.
Epilepsy panel and Autism Spectrum Disorders panels have been updated with multiple new genes. Discover more at www.asperbio.com/asper-neurogenetics/
Familial TAAD and related syndromes NGS panel has been updated with new genes. Visit www.asperbio.com/familial-taad-NGS-panel to see the complete list of genes.
Epilepsy NGS panel now covers the analysis of disease-associated non-coding variants. List of variants is available www.asperbio.com/list-of-non-coding-variants-covered-by-epilepsy-ngs-panel/
We now offer new panels for malignant hyperthermia and paroxysmal dyskinesia. Discover more at https://www.asperbio.com/asper-neurogenetics/
Panels of epilepsy and autism spectrum disorders have been updated with the WASF1 gene. For more information, visit https://www.asperbio.com/asper-neurogenetics/
Male Factor Infertility test has been upgraded from targeted mutation analysis to NGS panel with 60 genes associated with spermatogenic failure and meiotic arrest. Testing for Klinefelter syndrome and AZF deletions is also available. Visit www.asperbio.com/male-factor-infertility to see the full list of genes.
Our latest release is a panel of Congenital Disorders of Glycolysation targeting pathogenic variants in 49 clinically relevant genes. List of genes with more detailed information is available www.asperbio.com/congenital-disorders-of-glycolysation/
Genetic testing for Kallmann Syndrome is now available. New gene panel consists of 25 carefully selected genes and includes detection of single nucleotide polymorphisms (SNPs), insertions and deletions, as well as copy number variations (CNVs). Discover more at www.asperbio.com/asper-endocrinology/kallmann-syndrome-ngs-panel/
Dystonia and Spinocerebellar Ataxia panels are updated with MECR gene. Visit www.asperbio.com/asper-neurogenetics/ to learn more!
Prostate Cancer panel has been updated with 3 new genes. View the full list of genes www.asperbio.com/prostate-cancer-ngs-panel/
Updated versions of Vitreoretinopathy and comprehensive Eye Diseases NGS panels are now available. Order here www.asperbio.com/Asper_Ophthalmics_order_form
We have launched Asper Nephrology testing portfolio to expand our testing menu and cover more clinical areas. The new portfolio includes tests for common monogenic diseases, as well as complex disorders. To establish the genetic cause of renal diseases we use next-generation sequencing technology to accommodate a broad differential diagnosis. CNV analysis based on sequencing data is also available to enhance precise diagnosis. Visit https://www.asperbio.com/asper-nephrology/ to see the full list of tests.
We have integrated copy number variation (CNV) detection tool into our everyday workflow. CNV analysis is now available as a new testing option for all NGS panels and whole exome sequencing.
View the complete list of all tests www.asperbio.com/genetic-tests/
Asper Neurogenetics testing portfolio has been updated with Brunner syndrome test, and CNV analysis for all gene panels. See complete Asper Neurogenetics test menu here https://www.asperbio.com/asper-neurogenetics/
All NGS panels in Asper Otogenetics testing menu now include CNV analysis. Read more at www.asperbio.com/asper-otogenetics/